Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00007865 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00007865: Completed Phase 2 study, sponsored by University of Nebraska.
NCT00007865 is a Phase 2 study that has completed, run by University of Nebraska. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00007865, a Phase 2 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy combined with rituximab in treating patients who have recurrent or refractory non-Hodgkin's lymphoma.
Interventions
- DRUG carboplatin
- BIOLOGICAL rituximab
- DRUG etoposide
- DRUG ifosfamide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-09-01 |
| Est. Completion | 2008-04-22 |
| Phase | Phase 2 |
What the finished NCT00007865 record still lists
NCT00007865 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which carboplatin is the first listed.
NCT00007865 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00007865 about?
NCT00007865 is a clinical study titled "Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II ...
What is the current status of trial NCT00007865?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-09-01. Estimated completion is 2008-04-22.
What interventions are being tested in trial NCT00007865?
The interventions under investigation include: carboplatin (DRUG), rituximab (BIOLOGICAL), etoposide (DRUG), ifosfamide (DRUG).
Who is sponsoring clinical trial NCT00007865?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI